We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The US Food and Drug Administration (FDA) has sent a complete response letter to Insys Therapeutics rejecting its new drug application for Buvaya, a sublingual spray form of buprenorphine, an opioid analgesic.